A More Precise Gene Editor Takes Aim at Cystic Fibrosis Mutations

Cystic fibrosis is not one disease in the genetic sense -- it is more than a thousand. Over 1,700 distinct mutations in the CFTR gene can impair the protein responsible for moving salt and water across cells that line the lungs. When that transport fails, thick mucus accumulates, breathing becomes labored, and the lungs become a target for chronic bacterial infection.

Most patients who qualify rely on modulator drugs like Trikafta, which must be taken daily and cost, depending on insurance and circumstances, well over $300,000 per year in the United States. These drugs work for patients with specific mutations but are ineffective for others. Gene editing -- fixing the underlying DNA error once, potentially permanently -- offers a compelling alternative. The obstacle is precision: how do you change one letter in a genome of three billion without touching anything nearby?

The Bystander Problem in Base Editing

Base editing modifies individual nucleotides -- the chemical letters of DNA -- without cutting the double helix. One class of base editors converts cytosine (C) to thymine (T), which is precisely the correction needed for many cystic fibrosis mutations. But existing cytosine base editors have a known limitation: when multiple cytosine bases appear close together, the editor tends to modify more than one, altering neighbors it was never meant to touch.

These unintended changes are called bystander mutations. In laboratory tests, earlier tools produced bystander edits at rates as high as 50 to 60% at certain CFTR-relevant target sites. That level of off-target activity poses safety concerns that must be resolved before any clinical application.

"The issue is precision," said Tyler C. Daniel, a doctoral candidate in chemical and biomolecular engineering at Penn Engineering and co-first author of the new paper. "How do you restrict the editor so it only modifies the targeted letter C you want and leaves its neighbors alone?"

The challenge is not rare. Among the tens of thousands of known disease-causing C-to-T and T-to-C mutations this editor class can address, three-quarters involve cytosine pairs clustered in patterns where bystander editing is a risk.

Shortening the Leash

A base editor has two main components: a guide element that locates a specific DNA sequence, and an enzyme that performs the chemical modification. These two parts connect through a molecular linker, whose length and flexibility determine how freely the enzyme can move once it reaches its target.

The team's solution was architectural. By shortening and stiffening the linker, they constrained how far the enzyme could reach from the anchor point -- limiting its access to neighboring cytosines. They also modified the editor's binding affinity to reduce its tendency to act on nearby letters.

"It's a bit like editing a document," said Xue "Sherry" Gao, Presidential Penn Compact Associate Professor in Chemical and Biomolecular Engineering and Bioengineering at Penn Engineering, and co-senior author. "We can already identify and replace a particular letter in a specific word. How do we change only that one letter without accidentally altering the letters next to it?"

In tests in human cells, the redesigned editor reduced bystander mutations by more than 80% at the most accurate variant, while retaining substantial activity at the intended target. At several CFTR-relevant genetic positions, unintended edits fell from the 50-60% range to below 1%.

Testing in Disease-Relevant Cells

The team worked with human epithelial cells -- the cell type lining the airways that is directly affected by CFTR dysfunction. They first introduced specific cystic fibrosis-causing mutations into these cells to create disease models, then used the refined editor to correct those mutations, observing restored cellular function.

"We were also able to reverse those mutations and show improved cellular functions using the same editor, demonstrating the level of pinpoint gene-editing control this technology now offers," said Gang Bao, Foyt Family Professor of Bioengineering at Rice University and co-senior author.

The work is explicitly preclinical. No animal studies are reported in this paper, and human trials are not imminent. Delivery of a base editor to lung tissue in a living patient, achieving sufficient editing rates across enough cells to produce clinical benefit, and demonstrating long-term safety all remain open challenges. The research establishes proof of concept in cell culture -- an important step, but several stages removed from a therapy.

Beyond Cystic Fibrosis

The implications extend to any genetic disease caused by single-letter DNA mutations. The ability to create precise cellular models of specific mutations gives researchers a way to test existing drugs and explore new therapeutic strategies for conditions that affect small patient populations and may never be the subject of large clinical trials.

"The ability to precisely model disease-causing mutations gives us a much clearer window into how those mutations behave, including how they might respond to different therapies," said Gao. The study was supported by the National Institutes of Health (grants HL157714, HL169761, and T32NS091006) and the National Science Foundation Graduate Research Fellowship Program.